Pricing Log in Create free account
Friday 6 November 2026 Export XENE’s income statement to Excel — free account

Xenon Pharmaceuticals Inc.

XENE Healthcare Biotechnology

Xenon Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, down 20.5% from fiscal 2022.

Revenue
+100.7%
EPS
−3.74%
Free cash flow
−48.6%

Quarter to June 2026, against a year earlier

39.05 1.37 +3.64%
Market cap
$3.7B
P/E
0.0×
Fwd P/E
−8.1×
Dividend yield
—
F-score
n/a
Altman Z
37.76
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 1.68
Sold, $m 21.96
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — 2 — —
Sell 1 1 — 6 — — 2 — 2 — — —
Insider Ownership 7.90%

Capital & Financial Ratios $m

Size
Market Cap 3,650.00
Revenue ttm 16.93
Net income ttm (409.19)
Free cash flow ttm (338.53)
Net debt Q (930.69)
Valuation
P/E 0.00
Forward P/E (8.06) (negative: loss-making)
Price / sales 222.58 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 3.03
Financial health
Current ratio Q 21.02 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (7.98)
Growth
Revenue growth Q +100.70% (above 0%: growing)
Operating income growth Q −30.70% (below 0%: shrinking)
EPS, this year −5.56% (below 0%: weak)
EPS, next year A −1.40% (below 0%: weak)
Revenue, next year A −83.24% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +8.95%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 169×, against a ten-year median of 117×; over the ten years it ranged from 0.5× in 2017 to 534× in 2019.
P/S against its own 10 years 70.26%
10-year low 10-year high
P/B against its own 10 years 46.57%
10-year low 10-year high
EV/Sales against its own 10 years 69.45%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 638 627 549 931
Receivables 1 1 1 2
Inventory — — — —
Other — — — —
645 635 561 946
2023 2024 2025 Q'26
Payables 26 34 40 44
ST’ Debt — — — —
Other — — — —
27 36 42 45

Compound Annual Growth %

10y 5y 3y
Sales 3.15% 89.00% (38.45%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 25.29% 27.69% (6.92%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −1.16 Actual −1.11

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −1.16 −1.15 Beat by 0.01
Q4 FY25 −1.20 −1.31 Miss by 0.11
Q1 FY26 −1.17 −1.17 Met by 0.00
Q2 FY26 −1.16 −1.11 Beat by 0.05
Q3 FY26 −1.17 — Reports 9 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (1.17) (1.11) — — —
’25 (0.83) (1.07) (1.15) (1.31) (4.36)
’24 (0.62) (0.75) (0.81) (0.84) (3.01)
’23 (0.63) (0.72) (0.73) (0.64) (2.73)
’22 (0.35) (0.55) (0.57) (0.57) (2.06)
’21 (0.42) (0.51) (0.36) (0.57) (1.77)
’20 (0.22) 0.00 (0.25) (0.34) (0.81)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 8 — — — 8
’22 9 1 0 — 9
’21 4 2 8 4 18
’20 7 13 7 5 32
’19 — — 4 3 7
’17 0 0 0 0 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (89) (95) — — —
’25 (62) (64) (72) (81) (279)
’24 (46) (31) (50) (54) (181)
’23 (34) (33) (48) (35) (151)
’22 (18) (17) (30) (33) (98)
’21 (21) (13) (15) (21) (70)
’20 (13) (11) (11) (13) (48)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (89) (96) — — —
’25 (62) (64) (72) (82) (280)
’24 (46) (33) (50) (55) (184)
’23 (37) (35) (49) (35) (157)
’22 (19) (17) (31) (34) (101)
’21 (21) (14) (15) (21) (72)
’20 (14) (11) (12) (14) (51)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 2 0 — 7 32 18 9 — — 8 17 +17.2% 1 27 221 +209.1%
Gross margin, % 100.00 100.00 0.00 100.00 100.00 100.00 100.00 — — 100.00 28.40 0.0 pt
EBT (23) (31) (35) (42) (29) (79) (125) (183) (238) (345) (411) +35.1%
EBT margin, % (1,275.49) (9,872.67) 0.00 (609.43) (90.45) (427.88) (1,327.70) 0.00 0.00 (4,598.59) 0.00 (3,323.1) pt
Net income (23) (31) (34) (42) (29) (79) (125) (182) (234) (346) (409) +35.1%
Per share, $
Per share, $ Revenue 0.12 0.02 0.00 0.26 0.93 0.42 0.16 0.00 0.00 0.09 0.00 (2.3%)
Earnings (1.48) (1.71) (1.63) (1.54) (0.81) (1.77) (2.06) (2.73) (3.01) (4.36) (4.74) +12.8%
Cash flow (1.26) (1.60) (1.79) (0.18) (1.39) (1.59) (1.63) (2.26) (2.33) (3.52) (3.39) +12.1%
Capex (0.02) (0.02) (0.03) (0.05) (0.08) (0.05) (0.05) (0.08) (0.04) (0.01) (0.01) (6.2%)
Free cash flow (1.28) (1.61) (1.81) (0.23) (1.47) (1.64) (1.67) (2.34) (2.37) (3.53) (3.40) +11.9%
Book value 4.12 2.00 5.32 3.55 4.96 12.61 11.92 13.87 9.69 7.34 12.47 +6.6%
Shares, m 15 18 19 26 35 44 61 67 78 79 86 +19.9%
Valuation, ×
Valuation, × P/E 0.00 0.00 — 0.00 0.00 0.00 0.00 — — 0.00 0.00 0.0
P/S 67.45 166.55 — 47.84 16.52 73.92 171.27 — — 209.76 222.58 107.6
P/B 1.90 1.44 — 4.04 3.25 2.51 3.13 — — 6.11 3.03 3.2
EV/Sales 31.88 48.02 — 30.14 11.84 45.44 128.33 — — 178.92 169.19 67.8
EV/FCF (2.90) (0.51) — (35.98) (7.50) (11.71) (16.68) — — (10.82) (8.46) (12.3)
Cash, $m
Cash, $m Operating cash flow (20) (29) (35) (5) (48) (70) (98) (151) (181) (279) (338) +34.4%
Capex 0 0 (1) (1) (3) (2) (3) (6) (3) (1) (1) +12.4%
Free cash flow (20) (29) (35) (6) (51) (72) (101) (157) (184) (280) (339) +34.2%
Balance, $m
Balance, $m Working capital 62 41 117 101 167 545 578 618 600 519 901 +26.6%
Net debt (64) (37) (104) (126) (177) (552) (592) (638) (627) (549) (931) +26.9%
Shareholders’ equity 64 36 103 92 171 550 721 928 755 582 1,242 +27.8%
Returns, %
Returns, % ROA (34.99) (54.05) (37.52) (29.64) (16.63) (20.25) (18.84) (21.22) (26.58) (48.34) (41.54) (13.4) pt
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 (62.37) (46.16) (136.38) (709.28) (88.54) (709.3) pt
ROE (36.81) (61.51) (48.09) (44.52) (22.60) (21.84) (19.77) (22.12) (27.85) (51.76) (43.62) (14.9) pt
People
People Employees 94 81 92 104 129 153 213 259 327 370 — +16.4%
Revenue/emp, $m 0.02 0.00 0.00 0.07 0.25 0.12 0.04 0.00 0.00 0.02 — +0.6%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2025

Xenon Pharmaceuticals Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
RLAY Relay Therapeutics, Inc. $3.7B — (loss-making) — (loss-making) −95.44% (below 0%: shrinking) n/m +2.13% (above 0%: growing) 100.00% (25,949.71%) Compare
ACAD ACADIA Pharmaceuticals Inc. $3.7B 10.0× 33.4× +22.85% (above 0%: growing) −27.91% (below 0%: shrinking) +141.15% (above 0%: growing) 89.75% 20.95% Compare
XENE Xenon Pharmaceuticals Inc. $3.7B — (loss-making) — (loss-making) +100.70% (above 0%: growing) n/m −48.57% (below 0%: shrinking) 100.00% 0.00%
ABCL AbCellera Biologics Inc. $3.6B — (loss-making) — (loss-making) −76.29% (below 0%: shrinking) n/m +151.98% (above 0%: growing) 100.00% (1,550.05%) Compare
TNGX Tango Therapeutics, Inc. $3.5B — (loss-making) — (loss-making) −100.00% (below 0%: shrinking) n/m −4.58% (below 0%: shrinking) 0.00% 0.00% Compare
IOVA Iovance Biotherapeutics, Inc. $3.5B — (loss-making) — (loss-making) +80.07% (above 0%: growing) n/m +89.72% (above 0%: growing) 0.00% (19.73%) Compare
IRON Disc Medicine, Inc. $3.5B — (loss-making) — — n/m +7.83% (above 0%: growing) 0.00% 0.00% Compare
PBLS Parabilis Medicines, Inc. $3.4B — (loss-making) — — n/m — 100.00% (34,382.43%) Compare
VKTX Viking Therapeutics, Inc. $3.3B — (loss-making) — — n/m −47.01% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $3.5B — — −76.29% — +7.83% 44.88% (9.86%)

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 22 April 2026

Ownership

Directors and executive officers, together 2.91%
FMR LLC 9.13%
Avoro Capital Advisors LLC 5.86%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Xenon Pharmaceuticals Inc. (XENE) Latest News

29 Oct

Impact 4 · · GlobeNewswire

15 Oct

Impact 4 · · Zacks

9 Oct

Impact 4 · · Simply Wall St.
Impact 3 · · Simply Wall St.

1 Oct

Impact 3 · · Stocktwits
Impact 3 · · MT Newswires

29 Sep

Impact 4 · · TMX Newsfile

27 Sep

Impact 4 · · MarketBeat

22 Sep

Impact 4 · · Insider Monkey

21 Sep

Impact 4 · · TheStreet
Impact 4 · · Zacks
Impact 4 · · TIKR

19 Sep

Impact 4 ·

18 Sep

Impact 5 ·
Impact 4 · · Barchart
Impact 4 · · Proactive Investors
Impact 4 ·
Impact 4 ·
Impact 4 · · biopharmadive.com
Impact 3 ·
Impact 3 ·

17 Sep

Impact 5 ·

10 Sep

Impact 4 ·

4 Sep

Impact 4 ·

28 Aug

Impact 4 ·

26 Aug

Impact 4 ·

13 Aug

Impact 3 · · The Motley Fool transcript

7 Aug

Impact 4 ·
Impact 4 · transcript
Impact 3 · · MarketBeat transcript

XENE metrics, ten years each

stockrow.com/XENE · Data as of Mar 31, 2025 · For information only; not investment advice. · © 2026 stockrow.com